Polo-like Kinase 4: A Molecular Culprit in Skin Cancer Pathogenesis

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Skin cancer presents a significant global health challenge with increasing incidence and mortality.
• Novel therapeutic strategies are crucial for managing advanced and drug-resistant skin cancers.
• Polo-like kinases (PLKs), particularly PLK4, are implicated in cell cycle regulation and genomic stability, making them potential cancer targets.

Purpose of the Study:

• To review the known functions of polo-like kinase 4 (PLK4) in skin cancer.
• To explore potential mechanistic insights into PLK4's role in skin cancer progression.
• To identify research gaps for future investigations into PLK4 as a therapeutic target for skin cancer.

Main Methods:

• Literature review of existing studies on PLK4 function and inhibition.
• Extrapolation of evidence from PLK4 research in other cancer types (e.g., colorectal cancer, thyroid cancer, lymphomas, leukemia).
• Analysis of small-molecule PLK4 inhibitors and their clinical trial outcomes.

Main Results:

• PLK4 is overexpressed in several cancers, including skin cancer, and regulates centriole duplication.
• Dysregulation of PLK4 disrupts genomic integrity, contributing to tumorigenesis.
• Several PLK4 inhibitors, including CFI-400945, have shown preclinical efficacy, with CFI-400945 demonstrating modest anti-cancer activity in clinical trials.

Conclusions:

• PLK4 is a promising therapeutic target for skin cancer management.
• Further research is needed to fully elucidate PLK4's mechanisms in skin cancer and optimize therapeutic strategies.
• Targeting PLK4, alone or in combination with existing treatments, may offer novel options for difficult-to-treat skin cancers.